## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

### Board of Scientific Counselors, National Center for Injury Prevention and Control

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Board of Scientific Counselors, National Center for Injury Prevention and Control (BSC, NCIPC). This meeting is partially open to the public. There will be 15 minutes allotted for public comments at the end of the open session from 12:30 p.m. to 12:45 p.m. on August 20, 2020.

**DATES:** The meeting will be held on August 20, 2020, from 10:00 a.m. to 1:00 p.m., EST (OPEN) and August 20, 2020, from 1:30 p.m. to 5:00 p.m., EST (CLOSED).

**ADDRESSES:** Teleconference 1–800–369– 3110; Participant Code 7563795

FOR FURTHER INFORMATION CONTACT: Gwendolyn H. Cattledge, Ph.D., M.S.E.H., Deputy Associate Director for Science, NCIPC, CDC, 4770 Buford Highway NE, Mailstop S106–9, Atlanta, GA 30341, Telephone (770) 488–3953, Email address: NCIPCBSC@cdc.gov.

**SUPPLEMENTARY INFORMATION:** Portions of the meeting as designated above will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463.

*Purpose:* The Board will: (1) Conduct, encourage, cooperate with, and assist other appropriate public health authorities, scientific institutions, and scientists in the conduct of research, investigations, experiments, demonstrations, and studies relating to the causes, diagnosis, treatment, control, and prevention of physical and mental diseases, and other impairments; (2) assist States and their political subdivisions in preventing and suppressing communicable and noncommunicable diseases and other preventable conditions and in promoting health and well-being; and (3) conduct and assist in research and control activities related to injury. The BSC, NCIPC makes recommendations

regarding policies, strategies, objectives, and priorities; reviews progress toward injury prevention goals; and provides evidence in injury prevention-related research and programs. The Board also provides advice on the appropriate balance of intramural and extramural research, and the structure, progress and performance of intramural programs. The Board is designed to provide guidance on extramural scientific program matters, including the: (1) Review of extramural research concepts for funding opportunity announcements; (2) conduct of Secondary Peer Review of extramural research grants, cooperative agreements, and contracts applications received in response to funding opportunity announcements as they relate to the Center's programmatic balance and mission; (3) submission of secondary review recommendations to the Center Director of applications to be considered for funding support; (4) review of research portfolios, and (5) review of program proposals.

*Matters to be Considered:* The open portion of the agenda will include discussions on Health Equity, Violence, and Racism. All presentations will be followed by discussion by the BSC.

The closed portion of the agenda will focus on the Secondary Peer Review of extramural research grant applications received in response to three (3) Notice of Funding Opportunities (NOFOs): RFA-CE-20-002-"Grants to Support New Investigators in Conducting **Research Related to Preventing** Interpersonal Violence Impacting Children and Youth"; RFA-CE-20-005—"Rigorously Evaluating Approaches to Prevent Adult-Perpetrated Child Sex Abuse (CSA)"; and RFA-CE-20-006-""Research Grants to Prevent Firearm-Related Violence and Injuries (R01)", as well as PA-19-272/273-PHS 2019-02 "Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications" (Parent SBIR [R43/R44]). Agenda items are subject to change as priorities dictate.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2020–15029 Filed 7–10–20; 8:45 am]

## BILLING CODE 4163-18-P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

[Docket No. CDC-2020-0081]

#### Advisory Committee on Immunization Practices (ACIP)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting and request for comment.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the CDC, announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. Time will be available for public comment. The meeting will be webcast live via the World Wide Web.

**DATES:** The meeting will be held on July 29, 2020, from 10 a.m. to 4 p.m., EDT (times subject to change).

Written comments must be received on or before July 30, 2020.

**ADDRESSES:** For more information on ACIP please visit the ACIP website: http://www.cdc.gov/vaccines/acip/ index.html.

You may submit comments, identified by Docket No. CDC–2020–0081, by either of the following methods below. CDC does not accept comment by email.

• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments.

• *Mail:* Docket No. CDC–2020–0081, c/o Attn: July ACIP Meeting, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H24–8, Atlanta, GA 30329–4027.

Instructions: All submissions received must include the Agency name and Docket Number. All relevant comments received in conformance with the https://www.regulations.gov suitability policy will be posted without change to https://www.regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https://www.regulations.gov.